Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen.

Combination of the splenic marginal zone B-cell lymphoma (SMZL) and classical Hodgkin lymphoma (cHL) is extremely rare. We report a unique case with concurrent SMZL and cHL. The patient was a 63-year-old man who presented with fatigue and anemia, showing a splenomegaly and retroperitoneal lymphadenopathy.

Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group.

Background & Method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response.

Human endogenous retrovirus (HERV-K) particles in megakaryocytes cultured from essential thrombocythemia peripheral blood stem cells.

Objective: The aim of this study was to determine the extent of human endogenous retrovirus (HERV) gene translation in megakaryocytes cultured from peripheral blood stem cells of patients with essential thrombocythemia previously reported with platelet-associated HERV sequences and reverse transcriptase activity.

Materials And Methods: Terminally differentiated megakaryocytes derived from circulating stem cells in serum-free medium supplemented with stem cell factor and thrombopoietin were processed for electron microscopic immunostaining using a monoclonal antibody against the gag protein of HERV-K10 and an electron dense gold-labeled secondary antibody.

Results: We found that HERV-K gag protein was detected as clusters in the cytoplasm as well as associated with viral particles budding from the cell membrane and into intracellular vacuoles in megakaryocytes from two patients with essential thrombocythemia.

High-dose cyclophosphamide as salvage therapy for severe aplastic anemia.

Objective: The treatment options for patients with aplastic anemia who do not respond to conventional immunosuppression are limited. The aim of this study was to evaluate high-dose cyclophosphamide in patients with refractory severe aplastic anemia (SAA).

Materials And Methods: We treated 17 SAA patients with high-dose cyclophosphamide (50 mg/kg/day for 4 consecutive days) who previously did not respond to one or more courses of immunosuppressive therapy.

High-dose cyclophosphamide for refractory autoimmune hemolytic anemia.

High-dose cyclophosphamide, without stem cell rescue, has been used successfully to treat aplastic anemia and other autoimmune disorders. To determine the safety and efficacy of high-dose cyclophosphamide among patients with severe refractory autoimmune hemolytic anemia, we treated 9 patients with cyclophosphamide (50 mg. kg(-1).